Eftrenonacog Alfa

CHEMBL4594598 Phase 4 ได้รับการอนุมัติ Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This long-acting form of clotting factor IX is used to prevent and treat bleeding episodes in people with hemophilia B. It works by replacing the missing clotting factor needed for normal blood clotting.

ด้านการรักษา

Hematology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This long-acting form of clotting factor IX is used to prevent and treat bleeding episodes in people with hemophilia B. It works by replacing the missing clotting factor needed for normal blood clotting.

Yes, Eftrenonacog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594598. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Eftrenonacog Alfa บน PillFYI

ข้อมูลด่วน

ลิงก์ภายนอก

ChEMBL CHEMBL4594598

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.